Serum FAM19A5 in neuromyelitis optica spectrum disorders: Can it be a new biomarker representing clinical status?
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hye Lim | - |
dc.contributor.author | Seok, Hung Youl | - |
dc.contributor.author | Ryu, Han-Wook | - |
dc.contributor.author | Cho, Eun Bee | - |
dc.contributor.author | Kim, Bong Chul | - |
dc.contributor.author | Kim, Byoung Joon | - |
dc.contributor.author | Min, Ju-Hong | - |
dc.contributor.author | Seok, Jin Myoung | - |
dc.contributor.author | Shin, Ha Young | - |
dc.contributor.author | Kang, Sa-Yoon | - |
dc.contributor.author | Kwon, Oh-Hyun | - |
dc.contributor.author | Lee, Sang-Soo | - |
dc.contributor.author | Oh, Jeeyoung | - |
dc.contributor.author | Sohn, Eun-Hee | - |
dc.contributor.author | Huh, So-Young | - |
dc.contributor.author | Cho, Joong-Yang | - |
dc.contributor.author | Seong, Jae Young | - |
dc.contributor.author | Kim, Byung-Jo | - |
dc.date.accessioned | 2021-09-10T06:47:38Z | - |
dc.date.available | 2021-09-10T06:47:38Z | - |
dc.date.issued | 2020-11 | - |
dc.identifier.issn | 1352-4585 | - |
dc.identifier.issn | 1477-0970 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/19417 | - |
dc.description.abstract | Background: Neuromyelitis optica spectrum disorder (NMOSD) targets astrocytes and elevates the levels of astrocyte-injury markers during attacks. FAM19A5, involved in reactive gliosis, is secreted by reactive astrocytes following central nervous system (CNS) damage. Objective: To investigate the significance of serum FAM19A5 in patients with NMOSD. Methods: We collected clinical data and sera of 199 patients from 11 hospitals over 21 months. FAM19A5 levels were compared among three groups: NMOSD with positive anti-aquaporin-4 antibody (NMOSD-AQP4), other CNS demyelinating disease, and healthy controls. Results: The median serum FAM19A5 level was higher in the NMOSD-AQP4 (4.90 ng/mL (3.95, 5.79)) than in the other CNS demyelinating (2.35 ng/mL (1.83, 4.07), p < 0.001) or healthy control (1.02 ng/mL (0.92, 1.14), p < 0.001) groups. There were significant differences in the median serum FAM19A5 levels between the attack and remission periods (5.89 ng/mL (5.18, 6.98); 4.40 ng/mL (2.72, 5.13), p < 0.001) in the NMOSD-AQP4 group. Sampling during an attack (p < 0.001) and number of past attacks (p = 0.010) were independently associated with increased serum FAM19A5. Conclusion: Serum FAM19A5 was higher in patients with NMOSD-AQP4 and correlated with clinical characteristics. Thus, serum FAM19A5 may be a novel clinical biomarker for NMOSD-AQP4. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | SAGE Publications | - |
dc.title | Serum FAM19A5 in neuromyelitis optica spectrum disorders: Can it be a new biomarker representing clinical status? | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1177/1352458519885489 | - |
dc.identifier.scopusid | 2-s2.0-85074841378 | - |
dc.identifier.wosid | 000495327700001 | - |
dc.identifier.bibliographicCitation | Multiple Sclerosis, v.26, no.13, pp 1700 - 1707 | - |
dc.citation.title | Multiple Sclerosis | - |
dc.citation.volume | 26 | - |
dc.citation.number | 13 | - |
dc.citation.startPage | 1700 | - |
dc.citation.endPage | 1707 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.subject.keywordPlus | REACTIVE ASTROCYTES | - |
dc.subject.keywordPlus | AQUAPORIN-4 | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | ANTIBODY | - |
dc.subject.keywordAuthor | Neuromyelitis optica spectrum disorder | - |
dc.subject.keywordAuthor | astrocyte | - |
dc.subject.keywordAuthor | reactive gliosis | - |
dc.subject.keywordAuthor | CNS demyelinating disease | - |
dc.subject.keywordAuthor | MOG associated disease | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.